Increasing the activity of monoclonal antibody therapeutics by continuous chromatography (MCSGP).
The charged monoclonal antibody (mAb) variants of the commercially available therapeutics Avastin®, Herceptin® and Erbitux® were separated by ion-exchange gradient chromatography in batch and continuous countercurrent mode (MCSGP process). Different stationary phases, buffer conditions and two MCSGP configurations were used in order to demonstrate the broad applicability of MCSGP in the field of charged protein variant separation. Batch chromatography and MCSGP were compared with respect to yield, purity, and productivity. In the case of Herceptin®, also the biological activity of the product stream was taken into account as performance indicator. The robustness of the MCSGP process against feed composition variations was confirmed experimentally and by model simulations.
Müller-Späth
T
T
Institute for Chemical and Bioengineering, ETH Zurich, Wolfgang-Pauli-Strasse 10, Zurich, Switzerland.
Krättli
M
M
Aumann
L
L
Ströhlein
G
G
Morbidelli
M
M
D000911:Antibodies, Monoclonal / Q000302:isolation & purification* / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001709:Biotechnology / Q000379:methods*; D000068818:Cetuximab; D002852:Chromatography, Ion Exchange / Q000379:methods; D007155:Immunologic Factors / Q000302:isolation & purification* / Q000494:pharmacology*; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D000068258:Bevacizumab; D000068878:Trastuzumab; D000068818:Cetuximab